These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36671250)

  • 1. Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.
    Marino A; Stracquadanio S; Campanella E; Munafò A; Gussio M; Ceccarelli M; Bernardini R; Nunnari G; Cacopardo B
    Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.
    Bavaro DF; Belati A; Diella L; Stufano M; Romanelli F; Scalone L; Stolfa S; Ronga L; Maurmo L; Dell'Aera M; Mosca A; Dalfino L; Grasso S; Saracino A
    Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol (Fetroja) as a Treatment for Hospital-Acquired Pneumonia.
    Plaisance CJ; Borne GE; Daniel CP; Wagner MJ; Shelvan A; Mathew J; Ahmadzadeh S; Paladini A; Varrassi G; Shekoohi S; Kaye AD
    Cureus; 2024 Jan; 16(1):e52230. PubMed ID: 38352089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
    Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
    Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
    Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
    Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
    Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.
    Giacobbe DR; Ciacco E; Girmenia C; Pea F; Rossolini GM; Sotgiu G; Tascini C; Tumbarello M; Viale P; Bassetti M;
    Infect Drug Resist; 2020; 13():4697-4711. PubMed ID: 33402840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by
    Gatti M; Viaggi B; Rossolini GM; Pea F; Viale P
    Antibiotics (Basel); 2021 Dec; 11(1):. PubMed ID: 35052910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.
    Domingues S; Lima T; Saavedra MJ; Da Silva GJ
    Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.